Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer

By J. Tie, Yuxuan Wang, C. Tomasetti, Lu Li, S. Springer, I. Kinde, Natalie Silliman, M. Tacey, H. Wong, M. Christie and 16 more. Science Translational Medicine, 2016

1,312 citations recorded by the source corpus.

Detection of circulating tumor DNA in patients with resected stage II colon cancer provides evidence of residual disease. Footprints of persistent cancer Stage II colon cancer, which has spread through the wall of the colon but has not metastasized to the lymph nodes, can present a therapeutic dilemma. On one hand, these tumors can usually be completely removed by surgery, and the majority does not recur even without chemotherapy. On the other hand, it is difficult to determine which of these tumors will recur and to identify patients who would benefit from adjuvant chemotherapy after surgery. Tie et al. show that the presence of circulating tumor DNA in a patient’s blood after surgery is a sign of persistent tumor and a greatly increased risk of relapse, suggesting that this group of patients may require chemotherapy to prevent recurrence. Detection of circulating tumor DNA (ctDNA) after resection of stage II colon cancer may identify patients at the highest risk of recurrence and help inform adjuvant treatment decisions. We used massively parallel sequencing–based assays to evaluate the ability of ctDNA to detect minimal residual disease in 1046 plasma samples from a prospective cohort of 230 patients with resected stage II colon cancer. In patients not treated with adjuvant chemotherapy, ctDNA was detected postoperatively in 14 of 178 (7.9%) patients, 11 (79%) of whom had recurred at a median follow-up of 27 months; recurrence occurred in only 16 (9.8 %) of 164 patients with negative ctDNA [hazard ratio (HR), 18; 95% confidence interval (CI), 7.9 to 40; P < 0.001]. In patients treated with chemotherapy, the presence of ctDNA after completion of chemotherapy was also associated with an inferior recurrence-free survival (HR, 11; 95% CI, 1.8 to 68; P = 0.001). ctDNA detection after stage II colon cancer resection provides direct evidence of residual disease and identifies patients at very high risk of recurrence.

Subfields: Cancer Research, Oncology, Pathology and Forensic Medicine

View Paper: https://www.semanticscholar.org/paper/c7c97ed2216178da69515fa1f27d151bb89aef25

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Oncology

In Pathology and Forensic Medicine

Citations in the corpus

Liquid Biopsy: From Discovery to Clinical Application. (2021, result): “Encouraging results were also obtained in colorectal (94) and lung (95) cancers as two other major cancer types.”
Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities (2022, methodology): “Therefore, the alteration of Wnt and its related gene copy number in cfDNA can be used to diagnose CRC.”
Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments (2022, background): “BC, CRC DNA profiling Residual disease and relapse [120, 121]”
Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling (2017, background): “Circulating tumor DNA (ctDNA) has been shown to identify MRD shortly after completion of local therapy in patients with non-metastatic breast and colon cancers using assays that require personalization (7,8).”
Localised Colon Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up. (2020, background): “Indeed, ctDNA detection after stage II colon cancer resection has been demonstrated to provide direct evidence of residual disease and to identify patients at very high risk of recurrence.(71) The results of ongoing trials investigating the role of ctDNA as a tool to stratify patient’s risk of relap”
Enhancing the accuracy of next-generation sequencing for detecting rare and subclonal mutations (2018, background): “Liquid biopsies are being used to detect both drug-sensitizing and drug-resistance mutations 134 , low-level MRD after surgery 135,136 and to follow the response to treatment 137 .”